Companies Dominating the Strep Throat Treatment Market
- Pfizer Inc.
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Astrazeneca
- Novartis AG
- Bayer AG
- GSK Plc.
- Melinta Therapeutics
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Merck & co, Inc.
- Johnson & Johnson Service, Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi
- Mitsubishi Chemical Group Corp.
- Daiichi Sankyo Co Ltd.
Browse Key Market Insights with Data Illustration:
In the News
- Pfizer Inc., declared that the European Commission (EC) has provided marketing authorization for the organization’s 20-valent pneumococcal conjugate vaccine, commercialized in the European Union under the brand name PREVENAR 20®, for active vaccination for the avoidance of intrusive disease, pneumonia, and severe otitis media caused by Streptococcus pneumoniae in kids, children, and adolescents from 6 weeks to lower than 18 years of age.
- Pfizer Inc. announced top-line ABRYSVO® vaccine efficiency and protection information for a respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the continuous pivotal Phase 3 clinical trial RENOIR (RSV vaccine Efficiency study iNOlder adults Immunized against RSV disease).
